These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 15013931)

  • 1. Sibutramine and the management of obesity.
    Poston WS; Foreyt JP
    Expert Opin Pharmacother; 2004 Mar; 5(3):633-42. PubMed ID: 15013931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity.
    Luque CA; Rey JA
    Ann Pharmacother; 1999 Sep; 33(9):968-78. PubMed ID: 10492502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How does sibutramine work?
    Lean ME
    Int J Obes Relat Metab Disord; 2001 Dec; 25 Suppl 4():S8-11. PubMed ID: 11916106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A benefit-risk assessment of sibutramine in the management of obesity.
    Nisoli E; Carruba MO
    Drug Saf; 2003; 26(14):1027-48. PubMed ID: 14583064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sibutramine and the sympathetic nervous system in obese humans.
    Haynes WG; Egri Z
    Clin Auton Res; 2005 Jun; 15(3):189-92. PubMed ID: 15944867
    [No Abstract]   [Full Text] [Related]  

  • 8. Sibutramine. A review of its contribution to the management of obesity.
    McNeely W; Goa KL
    Drugs; 1998 Dec; 56(6):1093-124. PubMed ID: 9878996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity.
    Smith IG; Goulder MA;
    J Fam Pract; 2001 Jun; 50(6):505-12. PubMed ID: 11407998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sibutramine therapy in obese women--effects on plasma neuropeptide Y (NPY), insulin, leptin and beta-endorphin concentrations.
    Baranowska B; Wolińska-Witort E; Martyńska L; Chmielowska M; Mazurczak-Pluta T; Boguradzka A; Baranowska-Bik A
    Neuro Endocrinol Lett; 2005 Dec; 26(6):675-9. PubMed ID: 16380708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sibutramine lost and found.
    Bosello O; Carruba MO; Ferrannini E; Rotella CM
    Eat Weight Disord; 2002 Sep; 7(3):161-7. PubMed ID: 12452247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Sibutramine, an upcoming drug for weight loss acting on energy consumption and energy expenditure].
    Astrup A
    Acta Med Austriaca; 1998; 25(4-5):146-9. PubMed ID: 9879391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharma-clinics. Medication of the month. Sibutramine (Reductil)].
    Scheen AJ
    Rev Med Liege; 2001 Sep; 56(9):656-9. PubMed ID: 11702509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment.
    Van Gaal LF; Wauters MA; De Leeuw IH
    Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 2():35-40. PubMed ID: 9792480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sibutramine: new preparation. Slight weight loss; but also a slight rise in blood pressure ..
    Prescrire Int; 2001 Oct; 10(55):140-5. PubMed ID: 11824428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine.
    Apfelbaum M; Vague P; Ziegler O; Hanotin C; Thomas F; Leutenegger E
    Am J Med; 1999 Feb; 106(2):179-84. PubMed ID: 10230747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sibutramine-associated adverse effects: a practical guide for its safe use.
    Florentin M; Liberopoulos EN; Elisaf MS
    Obes Rev; 2008 Jul; 9(4):378-87. PubMed ID: 18034790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study.
    Gaciong Z; Placha G
    J Hum Hypertens; 2005 Sep; 19(9):737-43. PubMed ID: 15905888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.
    James WP; Caterson ID; Coutinho W; Finer N; Van Gaal LF; Maggioni AP; Torp-Pedersen C; Sharma AM; Shepherd GM; Rode RA; Renz CL;
    N Engl J Med; 2010 Sep; 363(10):905-17. PubMed ID: 20818901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.